Literature DB >> 870161

Direct leukocyte migration inhibition by myelin basic protein in exacerbations of multiple sclerosis.

W Sheremata, H Triller, J B Cosgrove, E H Eylar.   

Abstract

Studies in 13 normal subjects, 9 patients with multiple sclerosis (MS) within 3 weeks of exacerbation and 16 others 1 to 6 months after onset were carried out for evidence of cell-mediated hypersensitivity to myelin basic protein. Ten patients with stroke and 10 with Guillain-Barré syndrome were studied as additional controls. Peripheral leukocytes obtained by leukapheresis were packed into capillary tubes and allowed to migrate out onto glass in the presence or absence of myelin basic protein. Cells of patients within 3 weeks of an MS episode gave a mean migration index of 68 +/- 9%, and those 1 to 6 months after onset, 93 +/- 21%. For the entire MS group the mean index was 88 +/- 20%, for those with Guillain-Barré, 103 +/- 7%; and for the stroke patients, 107 +/- 11%. Results for the acutely ill MS patients were significant (P less than 0.005). The data are similar to those obtained using the migration inhibition factor assay but show that sensitized lymphocytes also elaborate a second mediator during acute exacerbations of illness. These observations strengthen evidence that sensitization to this potent encephalitogen occurs simultaneously with exacerbations of clinical illness.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870161      PMCID: PMC1879058     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  14 in total

1.  Serum migration-inhibitory activity in patients with lymphoproliferative diseases.

Authors:  S Cohen; B Fisher; T Yoshida; R E Bettigole
Journal:  N Engl J Med       Date:  1974-04-18       Impact factor: 91.245

2.  The Guillain-Barré syndrome and multiple sclerosis. In vitro cellular responses to nervous-tissue antigens.

Authors:  R E Rocklin; W A Sheremata; R G Feldman; M W Kies; J R David
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

3.  Effect of basic encephalitogenic protein and some peptides derived from it on the migration in agarose gel of leukocytes from patients with multiple sclerosis, other neurological diseases, or carcinoma.

Authors:  H Bergstrand; B Källén; O Nilsson
Journal:  Acta Neurol Scand       Date:  1974       Impact factor: 3.209

4.  Enzymatic degradation of myelin basic protein in central nervous system lesions of monkeys with experimental allergic encephalomyelitis.

Authors:  H C Rauch; E R Einstein; J Csejtey
Journal:  Neurobiology       Date:  1973

5.  Specific cleavage of the A1 protein from myelin with cathepsin D.

Authors:  S W Brostoff; W Reuter; M Hichens; E H Eylar
Journal:  J Biol Chem       Date:  1974-01-25       Impact factor: 5.157

6.  Leukocyte sensitivity to brain fractions in neurological diseases.

Authors:  E C Alvord; P C Hsu; R Thron
Journal:  Arch Neurol       Date:  1974-04

7.  Cellular interactions in the leukocyte migration inhibition system.

Authors:  S E Read; J B Zabriskie
Journal:  Transplant Proc       Date:  1972-06       Impact factor: 1.066

8.  Delayed hypersensitivity to myelin antigen in multiple sclerosis investigated with the leucocyte migration method.

Authors:  S Strandgaard; P N Jorgensen
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

9.  Macrophage receptors for migration inhibitory factor (MIF), migration stimulatory factor (MSF), and agglutinating factor.

Authors:  R A Fox; D S Gregory; J D Feldman
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

10.  Products of activated lymphocytes: leukocyte inhibitory factor (LIF) distinct from migration inhibitory factor (MIF).

Authors:  R E Rocklin
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.